| DC Field | Value | Language |
|---|
| dc.contributor.author | Khavinson, V. | - |
| dc.contributor.author | Linkova, N. | - |
| dc.contributor.author | Dyatlova, A. | - |
| dc.contributor.author | Kuznik, B. | - |
| dc.contributor.author | Umnov, R. | - |
| dc.date.accessioned | 2021-06-14T18:56:43Z | - |
| dc.date.available | 2021-06-14T18:56:43Z | - |
| dc.date.issued | 2020 | - |
| dc.identifier.citation | Peptides: Prospects for Use in the Treatment of COVID-19 / V. Khavinson [et al.] // Molecules. - 2020. - Vol.25, №19.-Art. 4389. - Doi: 10.3390/molecules25194389. - URL: https://www.mdpi.com/1420-3049/25/19/4389/htm | ru |
| dc.identifier.uri | http://dspace.bsu.edu.ru/handle/123456789/41846 | - |
| dc.description.abstract | There is a vast practice of using antimalarial drugs, RAS inhibitors, serine protease inhibitors, inhibitors of the RNA-dependent RNA polymerase of the virus and immunosuppressants for the treatment of the severe form of COVID-19, which often occurs in patients with chronic diseases and older persons. Currently, the clinical e cacy of these drugs for COVID-19 has not been proven yet | ru |
| dc.language.iso | en | ru |
| dc.subject | medicine | ru |
| dc.subject | infectious diseases | ru |
| dc.subject | COVID-19 | ru |
| dc.subject | immunity | ru |
| dc.subject | hemostasis | ru |
| dc.subject | drugs | ru |
| dc.subject | peptides | ru |
| dc.subject | immunomodulators | ru |
| dc.title | Peptides: Prospects for Use in the Treatment of COVID-19 | ru |
| dc.type | Article | ru |
| Appears in Collections: | Статьи из периодических изданий и сборников (на иностранных языках) = Articles from periodicals and collections (in foreign languages)
|
